Usman Azam, MD is the Global Head of the Cell & Gene Therapies Unit at Novartis Pharmaceuticals. Dr. Azam has extensive pharmaceutical and biotechnology industry experience in science, regulatory and commercial roles across a variety of disease areas. During his tenure at Novartis, Dr. Azam held prominent roles in Medical Affairs, Health Economics Outcomes Research, and Regulatory Affairs. Prior to Novartis, he founded Novaccel Therapeutics LLC, focused on accelerating assets in translational medicine. He held previous leadership roles at Aspreva Pharmaceutics, Johnson & Johnson and GlaxoSmithKline. Dr. Azam is a board certified obstetrician and gynecologist and is published in peer reviewed journals.

Luciano Rossetti – Head of Global Research & Development Luciano Rossetti, MD, is Executive Vice President, Global Head of Research & Development and a member of the Pharmaceutical Executive Committee.Before joining Merck Serono, Rossetti acted as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD. In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas. At MSD, he played a key role in shaping and implementing the development strategy of several potential breakthrough compounds such as Anti PD-1. He also restructured the clinical genetics group to better leverage the collaboration between discovery and clinical development.

Cyntia Genolet joined IFPMA in 2012 to work as the responsible for the anti-counterfeiting portfolio. In addition to this role, she leads since 2017 IFPMA engagement in Africa and deals with other Global Health policies. She also worked on policy issues related to biotherapeutic and regulatory domains. Cyntia holds a master’s degree in International Relations from the Graduate Institute of International and Development Studies in Geneva and a master’s of advanced studies in Health Economics and Management from HEC Lausanne.
Prior to joining IFPMA, she has worked for Sanofi in the office of relations with the International Institutions, in Geneva. She has built her professional experience working for NGOs, international organizations and governments in Africa, South America and Switzerland.

David Neal is Head of Policy at Polygeia and a final year medical student at the University of Cambridge. He holds a first class BA (Hons) degree in psychology and biological anthropology from the University of Cambridge and has worked at the World Health Organisation and Public Health Laboratory Ivo de Carneri, Zanzibar.

Rhys Wenlock is a third year Medical Student at Downing College, Cambridge and a researcher at Polygeia, a global health think-tank based at University of Cambridge. His global health research focuses on how the problems uncovered as a part of the international Ebola response could direct future development and health systems strengthening. Through the summer he will be working in Dar Es Salaam, Tanzania with the Cambridge Development initiative (CDI) to improve access to healthcare for marginalized communities.

Abigail Wood is a researcher with Polygeia, a global health think-tank based at University of Cambridge, where she is studying biochemistry. Her research interests focus on infectious diseases and she has project experience in strategic policy work for Lepra, a UK-based charity tackling leprosy, tuberculosis and other major infectious diseases. Abigail also serves as President of BlueSci, the Cambridge University Science Communications Society.

Director: DRA Head – South Africa and Southern Africa Country Group at Novartis
Dakshina held numerous regulatory positions in the pharmaceutical industry over the last 15 years based in South Africa. He has been with Novartis for 3.5 years managing the regulatory affairs function in this region. He has also provided support in regulatory policy and practice in the African region via his association with the IFPMA’s Africa Regulatory Network over the last 3 years. Within his position in Novartis, his achievements included a multitude of product submissions and registrations through the implementation of innovative strategies. In addition, he has also been invited into the pilot regulatory harmonisation project; ZAZIBONA project in the SADC region.

General Delegate of Fondation Chirac for Access to quality healthcare and medicines, Marc Gentilini is also President of the association OPALS (PanAfrican Organization for the Fight against AIDS) and Honorary President of the French Academy of Medicine. Grand Officer of the Légion of Honor, he has also been President of the French Red Cross from 1997 to 2004. Professor Marc Gentilini is a well-know specialist of the tropical diseases and has headed from 1970 to 1998 the department of neglected tropical diseases of the Hospital of La Pitié-Salepêtrière (Paris).

Paul Dearden is since May 2014 AbbVie’s Director, Regulatory Policy & Intelligence. Prior to that, he held various self employed consultancy assignments for 6 years. From 2004 to 2008, he worked at Brathay Learning & Development in a commercial role as Head of Corporate Business. He also stayed for 8 years with GSK’s and GlaxoWellcome R&D Ltd sepraretly and led their international regulatory affairs Policy & Intelligence group and before that various emerging markets responsibilities. He started his career as Senior Regulatory Executive of The Wellcome Foundation Ltd from 1993 to 1996.Paul Dearden holds a BSc Hons Degree in Physiology & Pharmacology from Manchester University, UK.

Caroline Mendy joined IFPMA in 2012 and is in charge of IFPMA regulatory affairs.
She holds a M.Sc. in Biochemistry from the University of Paris VII (France), and an M.Sc. in Pharmaceutical Sciences – Drug Development from the Faculty of Pharmacy of University of Montreal (Canada).
Caroline previously worked for the World Health Organization (WHO) as Technical Officer in the Essential Medicines and Pharmaceutical Policies department (EMP). Prior to WHO, Caroline worked at the Council of Europe, European Directorate for the Quality of Medicines and Healthcare (EDQM) in Strasbourg (France) as Scientific Administrator and at Pharmascience Inc. in Montreal (Canada) as Specifications and Drug Master Files (DMFs) Specialist.

Ms Estelle Michael, Senior Regulatory Policy Director, AstraZeneca and member of the IFPMA Regulatory Policy and Technical Standards Committee (RPTS). Estelle is currently focused on driving policy and advocacy for key emerging markets and is an active member of the Regulatory Policy and Technical Standards Committee (RPTS) of IFPMA.

Dr Konji Sebati is the current CEO of IPASA, the Innovative Pharmaceutical Association of South Africa. Konji has over 25 years’ experience in the Public and Private sector. Konji served as a Medical Officer in Paediatrics and Child Health for several years before managing 21 Primary Health Care clinics in Pretoria. She joined the private sector working first with Roche as Medical Advisor and then with Pfizer Pharmaceuticals as a senior Executive in Medical and Corporate Affairs, in South Africa and at the Pfizer Headquarters New York. In 2004 she was appointed South Africa’s Ambassador to Switzerland, The Vatican and Liechtenstein, and in 2008 was appointed Ambassador to France, UNESCO and the OECD. She worked as an International Civil Servant working for a United Nations Agency, WIPO, the World Intellectual Property Organisation, based in Geneva, as senior Director heading the Department of Traditional Knowledge and Global Challenges. Konji’s latest achievement was being appointed to the Board of the Medicines for Malaria Venture (MMV).

Konji has a Bachelor of Science degree from the University of the North (now University of Limpopo), an MBChb degree from University of Nairobi/Kenyatta Hospital, Kenya, a Diploma in Child Health from the College of Medicine, South Africa, and a Diploma in Public Health Planning and Health Services Management from the University of Witwatersrand.

Dr Abraham Palache is founder of FluPal Consultancy BV, a private company that provides expertise and services to Abbott, among others, in the field of influenza and influenza vaccinology. He’s co-founder of the European Scientific Working Group on Influenza (ESWI), a founding member of IFPMA’s Influenza Vaccine Supply International Task Force (IVS) where since 2004 he chairs the Policy Practice and Communication subgroup (PPC) of this group. He is also a member of the External Affairs Working Group of the Association of the European Vaccine Manufacturers (EVM). In 2006, he joined the Asia-Pacific Advisory Committee on Influenza (APACI) group as an industry representative. He served for more than 40 years Abbott Biologicals as Clinical Research Project leader, Director of Public Affairs for influenza and Global Government Affairs Director for Vaccines.

Dr. Grampp is a Director of R&D Policy at Amgen, where he leads external affairs related to biosimilars in Latin America and other regions. Prior to this role, he was Director of Regulatory Affairs, supporting regulatory agency interactions, technical strategy and submissions related to Amgen’s biosimilars development program while advocating for science-based implementation of biologics policies. Before his engagement on biosimilars, Dr. Grampp led technical teams responsible for development and quality oversight of Amgen’s biologics manufacturing processes. Dr. Grampp earned his bachelor’s degree in Chemical Engineering at the University of Wisconsin and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Grampp is the current Chair of IFPMA’s Biotherapeutics Group.

Soeren Mattke is not only a health policy expert but also a cardiologist. Today he is the Managing Director of RAND Health Advisory Services, the consulting practice of RAND Health. His work focuses on improving chronic illness care through redesign of delivery systems, payment reform and better products and technologies. Dr. Mattke serves as adviser to several international organizations, such as the OECD, the WHO, the European Commission and the World Economic Forum. Prior to coming to RAND, Dr. Mattke worked at the OECD in Paris on benchmarking healthcare systems in industrialized countries, in the healthcare practice of Bain & Company in Boston, at Abt Associates, a policy consulting firm in Cambridge, MA, and at Harvard University. He trained as an internist and cardiologist at the University of Munich. He lives in Boston with his wife Katharina and their three daughters and keeps his heart healthy with walking the dog, red wine and daily aspirin.

Dr. Paul Stoffels, M.D., is Chief Scientific Officer, and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. In this role, he works with R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda and is a member of the Johnson & Johnson Executive Committee.

He began his career as a physician in Africa, focusing on HIV and tropical diseases research. Paul chairs the Johnson & Johnson R&D Management Committee and provides oversight to the Johnson & Johnson Development Corporation (JJDC) and the Johnson & Johnson innovation centers, with the goal of catalyzing innovative science and technology.

Mario Ottiglio is Director of Public Affairs, Communications & Global Health Policy at IFPMA. He joined IFPMA in 2007 and held different positions of increasing responsibility. Mario develops and leads the implementation of global health policies as well as designs public affairs and communication strategies. He represents IFPMA in discussions with international organizations, governments and other nongovernmental organizations building consensus on policy decisions and partnerships.
Mario holds a master’s degree in Political Science and International Relations from the Oriental Studies University of Naples.
Prior to joining the IFPMA, Mario had worked as a consultant for governmental agencies and private firms.

Guilherme Cintra joined IFPMA in March 2005 and leads IFPMA’s advocacy with the WTO and the WIPO and runs the IFPMA Socio-Economic Research Network, which conducts international research and analytical work on different subjects relating to intellectual property, pharmaceutical innovation, and access to medicines. Guilherme studied economic history and social sciences in Geneva and Belo Horizonte. In his free time, he enjoys rock climbing and snowboarding. There are rumors he makes good capirinhas.

Pierre Van Damme is full professor at the University of Antwerp, Faculty of Medicine and Health Sciences. He chairs the Vaccine & Infectious Disease Institute (VAXINFECTIO, University of Antwerp); VAXINFECTIO is a consortium of three research units within the university: the Laboratory of Medical Microbiology (LMM), the Laboratory of Experimental Hematology (LEH), and the Centre for the Evaluation of Vaccination (CEV). It is recognized as ‘Centre of Excellence’ of the University of Antwerp and functions as WHO Collaborating Centre for the WHO European Region for the control and prevention of infectious diseases.
The CEV was founded in 1994 by Pierre Van Damme. The centre conducts research in 5 main areas: (1) (sero-)epidemiology of infectious diseases; (2) economic evaluation of public health interventions and mathematical modelling of infectious diseases; (3) assessment of protective efficacy and effectiveness of vaccines; (4) injection and diagnostic device research; (5) kinetics of vaccine-induced antibodies, including passive transfer of maternal antibodies.

Pierre Van Damme gained his MD from the University of Antwerp in 1984. He was recruited in 1985 to work on the epidemiology and prevention of hepatitis B in institutions for the mentally retarded. He subsequently obtained post-graduate degrees in health and economics, the evaluation of human corporal damage, and a master degree in occupational health. He obtained his PhD in epidemiology and social medicine in 1994 from the University of University of Antwerp, Belgium.

Mr. Kalland is responsible for the relationship with Pharmaceutical and Healthcare Manufacturers. Development and selling of services for Manufacturers.
Responsible for two Synergy workstreams for Walgreens Boots Alliance Development GmbH (Branded Pharma & Branded non Pharma)

Andrew Jenner is an Executive Director at JS Consulting Ltd. He joined IFPMA in late 2009 as the Director responsible for Innovation, Intellectual Property (IP) & Trade. From 2013 until 2015 Andrew worked as the Executive Director of Corporate Strategy & Legal Affairs at IFPMA. Prior to joining IFPMA, he held a number of policy roles in the UK Government including the principal UN/WTO negotiator on IP, Trade & Development for the UK Intellectual Property Office. He also led the UK Government’s IP Crime Strategy which pioneered the creation of a Governmental, multi-enforcement agency & industry taskforce. Before joining Government, he worked in the automotive industry as a quality control advisor. He is a Fellow of the Chartered Institute of Management and a Member of the Institute of Engineering & Technology having a Bachelor degree in Engineering and a Master of Laws.

Dr Downham studied for a bachelor of sciences degree (with honours) in industrial biology at London South Bank Polytechnic (UK) which included a placement with Boehringer Mannheim, now Roche (Germany). He then completed a PhD in biochemical engineering (Birmingham University, UK), a post-doctoral fellowship in bio-molecular sciences (Liverpool John Moores University, UK) and a post-graduate certificate in further/higher education (Bolton Institute, UK).
He joined the biopharmaceutical industry in 1997 and has worked for Protherics (UK), Bavarian Nordic (Germany), Morphosys (Germany) and Novartis Vaccines & Diagnostics (Italy). Throughout this time Dr Downham worked on preclinical and early clinical development of vaccine, antibody or enzyme therapies for infectious, hypertension, inflammatory and oncology indications. He was a certified European Registered Toxicologist (2010-2015) and has co-authored 29 publications/abstracts and 3 international patents.
Dr Downham joined the influenza vaccine franchise of AstraZeneca/Medimmune (UK) in February 2013 as an Associate Director, Flu Manufacturing Sciences & Technology within the Biopharmaceutical Development (R&D) department.

Born in London, Cary Adams has a BSc Honours degree in Economics, Computing and Statistics from the University of Bath, United Kingdom and a Masters degree (with Distinction) in Business Administration. He is a Harvard Business School Alumni having attended the School’s Executive General Management programme in 2003. In 2009, Cary made a career change, moving from the management of international businesses in the banking sector to become CEO of UICC based in Geneva.

Emilio A. Emini, Ph.D., is Senior Vice President of Vaccine Research and Development at Pfizer Inc., a position into which he transitioned subsequent to Pfizer’s acquisition of Wyeth Pharmaceuticals in late 2009. Dr. Emini joined Wyeth as Executive Vice President of Vaccine Research and Development in November 2005. At Wyeth, he led the R&D efforts that resulted in licensure of Prevnar 13, Pfizer’s vaccine for the prevention of pneumococcal disease. Currently, Dr. Emini leads Pfizer’s worldwide vaccine research and development programs.

Ruth March, VP and Head of Personalised Healthcare and Biomarkers, leads AstraZeneca’s function of world class diagnostic and biomarker science experts, delivering companion diagnostic tests to target AZ drugs to the right patients across each therapy area and all phases of development. She has driven adoption of Personalised Healthcare approaches by 70% of AstraZeneca’s pipeline, partnering with a strategic network of diagnostic companies to ensure delivery to global clinical trials and marketed products.

Dr. Anke Post is a medical fellow in neuroscience discovery and clinical investigation at Eli Lilly and Company’s Erl Wood research facility in the UK. The majority of her 20 years of professional activity has been dedicated to preclinical research, to medical duties and to clinical (pharmaceutical) development. Dr. Post completed post-graduate studies in basic and clinical neuroscience research at the Humboldt University of Berlin and at the Max-Planck Institute of Psychiatry (MPI) in Munich, Germany. She joined Lilly in 2011 after several years leading clinical trials for neuroscience development programs as well as in business development activities. At Lilly she works as clinical lead for several important neuroscience projects, is a member of the drug discovery leadership team, is the lead physician for the early clinical portfolio.

Ronald T. Piervincenzi, Ph.D., is the Chief Executive Officer of the United States Pharmacopeial Convention (USP). For 12 years Dr. Piervincenzi was a partner and leader in McKinsey & Company's Global Pharmaceutical and Medical Products Practice where, among other responsibilities, he launched McKinsey's global drug safety, medical and regulatory service line. Most recently, as a VP in Development Sciences with Biogen Idec, he launched a new group (Value-Based Medicine) focused on applying tools and technologies of personalized medicine to the multiple sclerosis disease area. Dr. Piervincenzi earned his M.S. and Ph.D. from Duke University in Biomedical Engineering, with research focused on protein engineering. He is the founder of multiple non-profits in the community service and scientific spaces including serving currently as Board Chair for the Newark Mentoring Movement and the NextStep Translational Research Foundation.